Report on the second endocrine aspects of duchenne muscular dystrophy conference December 1-2, 2010, Baltimore, Maryland, USA

Neuromuscular Disorders

Volumn 21, Issue 8, 2011, Pages 594-601

  Leung, D G ^a,b   Germain Lee, E L ^a,b   Denger, B E ^c   Wagner, K R ^a,b  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Parent Project Muscular Dystrophy   (United States)

Author keywords

Bone health; Duchenne muscular dystrophy; Endocrinology; Metabolism; Obesity; Puberty; Self esteem

Indexed keywords

ACE 031; ALENDRONIC ACID; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; DEFLAZACORT; HUMAN GROWTH HORMONE; HYDROCORTISONE SODIUM SUCCINATE; MYOSTATIN; OXANDROLONE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PREDNISONE; PROTEIN; PROTEIN INHIBITOR; RECOMBINANT PARATHYROID HORMONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SOMATOMEDIN; SOMATOMEDIN 1; TESTOSTERONE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BACKACHE; CONFERENCE PAPER; DELAYED PUBERTY; DRUG FEVER; DRUG INTERMITTENT THERAPY; DUCHENNE MUSCULAR DYSTROPHY; ENDOCRINE DISEASE; FRACTURE; GROWTH DISORDER; HEALTH CARE MANAGEMENT; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; INTRACRANIAL HYPERTENSION; MEDICAL EDUCATION; METABOLIC DISORDER; MUSCLE GROWTH; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PUBERTY; SCOLIOSIS; SELF ESTEEM; SHORT STATURE; UNITED STATES; WEIGHT CONTROL;

ADRENAL CORTEX HORMONES; ENDOCRINE SYSTEM; GROWTH DISORDERS; HUMANS; MARYLAND; METABOLIC DISEASES; MUSCULAR DYSTROPHY, DUCHENNE; OBESITY; OSTEOPOROSIS;

EID: 79960911228     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2011.04.008     Document Type: Conference Paper

References (35)

1. Bianchi M.L., Biggar D., Bushby K., et al. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord 2011.
2. Al-Harbi T.M., Bainbridge L.J., McQueen M.J., Tarnopolsky M.A. Hypogonadism is common in men with myopathies. J Clin Neuromuscul Disord 2008, 9:397-401.
3. Amory J.K., Watts N.B., Easley K.A., et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004, 89:503-510.
4. Wang C., Cunningham G., Dobs A., et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004, 89:2085-2098.
5. Nagel B.H., Mortier W., Elmlinger M., et al. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatr 1999, 88:62-65.
6. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995, 74:S70-S92.
7. Biggar W.D., Gingras M., Fehlings DL V.A., Harris Steele.C.A. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001, 138:45-50.
8. Griggs R.C., Moxley R.T., Mendell J.R., et al. Randomized, double-blind trial of mazindol in Duchenne dystrophy. Muscle Nerve 1990, 13:1169-1173.
9. Cittadini A., Ines Comi L., Longobardi S., et al. A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. Eur Heart J 2003, 24:664-672.
10. Frank G.R., Smith R.E. Effective growth hormone therapy in a growth hormone deficient patient with Duchenne muscular dystropy without evidence of acceleration of the dystrophic process. J Pediatr Endocrinol Metab 2001, 14:211-214.
11. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2004CD003725.
12. Rapisarda R., Muntoni F., Gobbi P., Dubowitz V. Duchenne muscular dystrophy presenting with failure to thrive. Arch Dis Child 1995, 72:437-438.
13. Martigne L., Salleron J., Mayer M., et al. Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit. Br J Nutr 2011, 105:1486-1491.
14. Moxley R.T., Pandya S., Ciafaloni E., Fox D.J., Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010, 25:1116-1129.
15. Biggar W.D., Harris V.A., Eliasoph L., Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006, 16:249-255.
16. Houde S., Filiatrault M., Fournier A., et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008, 38:200-206.
17. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93.
18. Bushby K., Griggs R. 145th ENMC International Workshop: planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD), 22-24th October 2006, Naarden, The Netherlands. Neuromuscul Disord 2007, 17:423-428.
19. Wagner K.R., Lechtzin N., Judge D.P. Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 2007, 1772:229-237.
20. Moxley R.T., Ashwal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the quality standards subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005, 64:13-20.
21. Bothwell J.E., Gordon K.E., Dooley J.M., et al. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr (Phila) 2003, 42:353-356.
22. Soderpalm A.C., Magnusson P., Ahlander A.C., et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 2007, 17:919-928.
23. Bianchi M.L., Mazzanti A., Galbiati E., et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 2003, 14:761-767.
24. Larson C.M., Henderson R.C. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 2000, 20:71-74.
25. McDonald D.G., Kinali M., Gallagher A.C., et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 2002, 44:695-698.
26. McMillan H.J., Campbell C., Mah J.K. Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey. Can J Neurol Sci 2010, 37:195-205.
27. King W.M., Ruttencutter R., Nagaraja H.N., et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007, 68:1607-1613.
28. Quinlivan R., Roper H., Davie M., et al. Report of a muscular dystrophy campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 2005, 15:72-79.
29. Quinlivan R, Shaw N, Bushby K. 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27-29 November 2009, Naarden, The Netherlands. Neuromuscul Disord;20:761-769.
30. Biggar W.D., Bachrach L.K., Henderson R.C., et al. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 2005, 15:80-85.
31. Ross A.C., Manson J.E., Abrams S.A., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-58.
32. Bianchi M.L., Morandi L., Andreucci E., et al. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporos Int 2011, 22:529-539.
33. Fenichel G.M., Griggs R.C., Kissel J., et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001, 56:1075-1079.
34. Kong A., Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002, 2:692-699.
35. Sattler F.R., Castaneda-Sceppa C., Binder E.F., et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab 2009, 94:1991-2001.